Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)

Published:2019-09-10 Issue:4 Volume:9 Page:719-724
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Villani Alessia,Megna Matteo,Fabbrocini Gabriella,Cappello Milena,Luciano Maria Antonietta,Costa Claudia,Scalvenzi Massimiliano

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13555-019-00323-4.pdf

Reference18 articles.

1. Mohan SV, Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40–5.

2. Gaulin C, Sebaratnam DF, Fernández-Peñas P. Quality of life in non-melanoma skin cancer. Australas J Dermatol. 2015;56(1):70–6.

3. Abedini R, Nasimi M, Noormohammad Pour P, Moghtadaie A, Tohidinik HR. Quality of life in patients with non-melanoma skin cancer: implications for healthcare education services and supports. J Cancer Educ. 2018. https://doi.org/10.1007/s13187-018-1368-y .

4. Scalvenzi M, Villani A, Mazzella C, Cappello M, Salvatores GF, Costa C. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758–60.

5. Frampton JE, Basset-Séguin N. Vismodegib: a review in advanced basal cell carcinoma. Drugs. 2018;78(11):1145–56. https://doi.org/10.1007/s40265-018-0948-9 .

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vismodegib in Gorlin‐Goltz syndrome: A systematic review;Australasian Journal of Dermatology;2024-06-12

2. An update on the current and emerging pharmacotherapies for basal cell carcinomas;Expert Opinion on Pharmacotherapy;2023-11-18

3. Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire;Dermatology Practical & Conceptual;2023-07-31

4. Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data;Cancers;2023-07-14

5. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation;Expert Opinion on Drug Safety;2023-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3